Pyoderma gangrenosum complicating ulcerative colitis: An alternative treatment with iloprost

Current Therapeutic Research - Clinical and Experimental

Volumn 60, Issue 6, 1999, Pages 357-362

  Mazzone, Antonino ^a   Cusa, Chiara ^a   Mazzucchelli, Iolanda ^a   Rosso, Renato ^a   Vezzoli, Monia ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Antiadhesion therapy; Microcirculation; Pyoderma gangrenosum; Ulcerative colitis

Indexed keywords

CELL ADHESION MOLECULE; CORTICOSTEROID; ILOPROST; PROSTACYCLIN DERIVATIVE;

ADULT; ANIMAL TISSUE; ARTICLE; CASE REPORT; CELL INTERACTION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MICROCIRCULATION; PHAGOCYTE; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; SCAR; SKIN DEFECT; ULCERATIVE COLITIS;

EID: 0032869442     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(99)80012-5     Document Type: Article

References (24)

1. Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: Classification and management. J Am Acad Dermatol 1996;34:395-409.
2. Dwarakanath AD, Yu LG, Brookes C, et al. Sticky neutrophils, pathergic arthritis and response to heparin in pyoderma gangrenosum complicating ulcerative colitis. Gut. 1995;37:585-588.
3. Harris AJ, Rega P, Burge S. Lesson of the week: Early diagnosis of pyoderma gangrenosum is important to prevent disfigurement. BMJ. 1998;316:52-53.
4. Salmon P, Rademaker M, Edwards L. A continuum of neutrophilic disease occurring in a patient with ulcerative colitis. Australas J Dermatol. 1998;39:116-118.
5. Jones SC, Banks RE, Haidar A, et al. Adhesion molecules in inflammatory bowel disease. Gut. 1995;36:724-730.
6. Springer TA. Traffic signals for leukocyte recirculation and leukocyte emigration: The multisteps paradigm. Cell. 1994;76:301-314.
7. Granger DN, Cubes P. The microcirculation and inflammation: Modulation of leukocyte-endothelial cell adhesion. J Leukocyte Biol. 1994;55:662-675.
8. Marcus AJ. Thrombosis and inflammation as multicellular processes: Significance of cell-cell interaction. Semin Hematol. 1994;31:261-268.
9. Carlos TM, Harlan JM, Leukocyte-endothelial adhesion molecules. Blood. 1994;84:2068-2101.
10. Beekhuizen H, Blokland I, van Furth R. Cross-linking of CD14 molecules on monocytes results in a CD11/CD18 and ICAM-1 dependent adherence to cytokine-stimulated human endothelial cells. J Immunol. 1993;150:950-959.
11. Wright SD, Weitz JI, Huang AJ, et al. Complement receptor type three (CD11b/CD18) of human polymorphonuclear leukocytes recognizes fibrinogen. Proc Natl Acad Sci USA. 1988;85:7734-7738.
12. Ciuffetti G, Lombardini R, Paltriccia R, et al. Human leukocyte-endothelial interactions in peripheral arterial occlusive disease. Eur J Clin Invest. 1994;24:65-68.
13. Chow RK, Ho VC. Treatment of pyoderma gangrenosum. J Am Acad Dermatol. 1996;34:1047-1060.
14. Futami H, Kodaira M, Furuta T, et al. Pyoderma gangrenosum complicating ulcerative colitis: Successful treatment with methylprednisolone pulse therapy and cyclosporine. J Gastroenterol. 1998;33:408-411.
15. Lim KK, Su WP, Schroeter AL, et al. Cyclosporine in the treatment of dermatologic disease: An update. Mayo Clin Proc. 1996;71:1182-1191.
16. Burruss JB, Farmer ER, Callen JP. Chlorambucil is an effective corticosteroid-sparing agent for recalcitrant pyoderma gangrenosum. J Am Acad Dermatol. 1996;35:720-724.
17. Gupta AK, Shear NH, Sauder DN. Efficacy of human intravenous immune globulin in pyoderma gangrenosum. J Am Acad Dermatol. 1995;32:140-142.
18. Abu Elmagd K, Jegasoty BV, Acherman CD, et al. Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum. Transplant Proc. 1991;23:3328-3329.
19. Sanchez Roman J, Castillo Palina MJ, Acana Medina C, Rodriguez Canas T. The treatment of cyclosporine. A resistant pyoderma gangrenosum with recombinant interferon alfa 2. Med Clin (Barc). 1995;8:517-518. Letter.
20. Karakura T, Usuki K, Kanzaki T. Nicotine for pyoderma gangrenosum. Comment on: Lancet. 1994;334:898, Lancet. 1995;45:1058.
21. Moncada S. Biological importance of prostacyclin. Br J Pharmacol. 1982;76:3-31.
22. Grant S, Goa K. Iloprost (review). Drugs. 1992;43:889-924.
23. Mazzone A, Mazzucchelli I, Fossati G, et al. Iloprost. Effects on phagocytes in patients suffering from ischemic diseases: In vivo evidence for down regulation of aMb2 integrin. Eur J Clin Invest. 1996;26:860-866.
24. Mazzone A, Cusa C, Bucci L, et al. Effect of iloprost infusion on microcirculation is independent of nitric oxide metabolites and endothelin-1 in chronic peripheral ischemia. Eur J Clin Invest. 1999;29:1-5.